Ovid Therapeutics (NASDAQ: OVID) stock rose by more than 18% as of 12 a.m. today. The biopharmaceutical company is devoted to developing medicines for people with epilepsy and other brain conditions, and today's rise follows some positive newsflow on its most exciting pipeline program, OV329. A next-generation treatment The company defines OV329 as a "next-generation GABA-aminotransferase (GABA-AT) inhibitor being developed as a potential medicine for rare and treatment-resistant forms of epilepsy and sei ...